Aquestive Therapeutics (AQST) Operating Expenses (2017 - 2026)

Aquestive Therapeutics has reported Operating Expenses for 10 years, with the latest figure at $22.0 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 3.14% year-over-year to $22.0 million in Q2 2026; TTM through Jun 2026 was $106.8 million, a 10.44% increase from a year earlier, with the FY2025 full-year figure at $115.6 million, up 30.87% from the prior year.
• Operating Expenses was $22.0 million for Q2 2026 at Aquestive Therapeutics, up from $18.6 million in the prior quarter.
• The five-year high for Operating Expenses was $41.9 million in Q4 2025, with the low at $15.4 million in Q3 2023.
• Average Operating Expenses over 5 years is $22.2 million, with a median of $21.4 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses jumped 64.48% in 2025, then slumped 33.59% in 2026.
• Over 5 years, Operating Expenses stood at $21.4 million in 2022, then slipped by 20.0% to $17.1 million in 2023, then soared by 48.66% to $25.4 million in 2024, then surged by 64.48% to $41.9 million in 2025, then slumped by 47.34% to $22.0 million in 2026.
• The last three Operating Expenses figures came in at $22.0 million (Q2 2026), $18.6 million (Q1 2026), and $41.9 million (Q4 2025), per Business Quant data.